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Abstract. The aryl hydrocarbon receptor (AHR) is tran-
scriptionally active in the form of a heterodimer with the 
AHR nuclear translocator, which then binds to the xenobiotic 
responsive element. AHR was originally discovered via its 
ligand, the polychlorinated hydrocarbon, 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin (TCDD). In this study, we investigated 
whether TCDD regulates the growth of human liver cancer 
HepG2 cells in vitro. TCDD (0.1-100 nM) was found to exert 
suppressive effects on the colony formation and proliferation 
of HepG2 cells, and stimulatory effects on the death of HepG2 
cells when the cells reached subconfluence. The effects of 
TCDD on the HepG2 cells were abolished by culture with 
CH223191, an inhibitor of AHR signaling. The effects of 
TCDD were dependent on the concentration of serum, which 
contains various signaling factors. The effects of TCDD were 
not potentiated by culture with tumor necrosis factor-α, which 
activates the signaling of nuclear factor-κB (NF-κB). The 
results of western blot analysis revealed that TCDD increased 
the protein levels of p53, Rb, p21, and regucalcin, which are 
suppressors of the growth of tumor cells. Moreover, TCDD 
enhanced the NF-κB p65, β-catenin, signal transducer and 
activator of transcription 3 (STAT3), Ras and Akt levels. Thus, 
the findings of this study indicate that TCDD may suppress 
liver cancer cell growth through various signaling pathways, 
mediated by AHR and its-related co-factors. Of note, the 
effects of TCDD were found to be potentiated by gemcitabine, 
which induces nuclear DNA damage in cancer cells, suggesting 
that their combined use may have potential as a suppressor of 
tumor cell growth.
Introduction
The aryl hydrocarbon receptor (AHR) is a ligand-activated 
transcription factor belonging to the family of basic 
helix-loop-helix Per-Arnt-Sini transcription factors (1,2). AHR 
is transcriptionally active in the form of a heterodimer with the 
AHR nuclear translocator (ARNT), which binds to xenobiotic 
responsive elements (1,2). AHR was originally discovered 
through its binding to the polychlorinated aromatic hydro-
carbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
polycyclic aromatase hydrocarbons, such as benzo[a]
pyrene (B[a]P) and polychlorinated biphenyls (PCBs) (1,2). 
In recent years, many dietary compounds have been iden-
tified as AHR agonists (3-7). AHR signaling, which is 
regulated through various factors, may play a crucial role in 
the regulation of diverse cellular and biological processes. The 
canonical target genes for AHR are cytochrome P450 isoforms 
(CYP1A1, CYP1A2 and CYP1B1), which are implicated in 
the metabolism of xenobiotics and endogenous compounds, 
including eicosanoids (8). The AHR-dependent pathway is 
also involved in the process of chemically-induced toxicity and 
carcinogenesis through the production of free radicals and the 
conversion of pro-carcinogens to ultimate genotoxic carcino-
gens via metabolism by these enzymes (8,9). Moreover, the 
xenobiotic and ligands of AHR are linked to various toxicities 
and pathologies in humans, including cancer (10-16). However, 
the molecular mechanisms responsible for the biological 
effects induced by non-genotoxic AHR ligands are poorly 
understood, and the mechanistic link between CYP induction 
and TCDD-mediated hepatotoxicity or immunotoxicity is 
complex (17,18). Of note, a previous study on AHR-null mice 
have demonstrated that the AHR, in the absence of exogenous 
ligands, is involved in several physiological processes (19). 
These investigations demonstrate a pivotal role for AHR 
beyond xenobiotic metabolism (20).
The AHR interacts with signaling pathways, control-
ling not only the cellular response to toxic and carcinogenic 
compounds, but also physiological functions (21). The disorder 
of the fine homeostatic regulations of cell proliferation and 
apoptosis may lead to toxic processes, such as tumor promo-
tion, immunosuppression and teratogenicity. AHR activation 
may lead to either the stimulation or inhibition of proliferation 
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or apoptosis. The physiological function of the AHR in the 
absence of exogenous ligand may differ from its toxicological 
role after binding exogenous ligand. Mice expressing consti-
tutively active AHR exhibited an enhanced development of 
liver tumors in a model of hepatocarcinogenesis (22). On the 
contrary, the AHR may also possess tumor suppressor activi-
ties in the liver (23). Notably, AHR deficiency exerts a profound 
effect on the hepatic system; thus, AHR-null mice have a 
reduced liver size and portal fibrosis (24‑26). Other studies 
have indicated that TCDD can partially impair liver regen-
eration in mice following two-thirds partial hepatectomy (27). 
AHR signaling may serve to adjust liver repair and to block 
tumorigenesis by modulating stem-like cells and β-catenin 
signaling (28). Moreover, the AHR has been demonstrated to 
adjust liver regeneration after acute toxic injury and protect 
against liver carcinogenesis (29). From these findings, it has 
been proposed that non-toxic AHR agonists may be useful for 
preventing the growth of liver tumors.
We hypothesized that AHR signaling may inhibit the 
proliferation and stimulate the death of cancer cells, leading 
to the suppression of tumor growth. These effects of AHR 
signaling are not yet fully understood. The current study was 
thus undertaken to determine the effects of TCDD, an agonist 
of AHR, on the proliferation and death of human liver cancer 
HepG2 cells in vitro. We demonstrate a novel finding that cell 
culture with TCDD at comparatively low levels suppresses the 
proliferation and stimulates the death of human liver cancer 
HepG2 cells in vitro, and that these effects are mediated 
through mechanistic pathways involved in AHR signaling 
activity and other related signaling factors.
Materials and methods
Materials and reagents. TCDD (>99.99% purity; Dow 
Chemicals Co., Midland, MI, USA) was dissolved in 
dimethylsulfoxide (DMSO) and stored in the dark at ‑20˚C 
until use. α-minimum essential medium (α-MEM; with 
glutamine) and antibiotics [penicillin (10,000 U/ml) and 
streptomycin (10,000 µg/ml); P/S] were purchased from Gibco 
Life Technologies Corp. (Grand Island, NY, USA). Fetal 
bovine serum (FBS) was obtained from Omega Scientific 
Inc. (Tarzana, CA, USA). 2-Methyl-2H-pyrazole-3-carboxylic 
acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH223191) was 
obtained from Selleckchem Co. (Houston, TX, USA) and was 
dissolved in DMSO. Tumor necrosis factor-α (TNF-α) was 
obtained from R&D Systems (Minneapolis, MN, USA) and 
gemcytabine from Hospira, Inc. (Lake Forest, IL, USA) and 
were diluted in phosphate-buffered saline (PBS). Caspase-3 
inhibitor (CAS 169332-60-9-Calbiochem), crystal violet 
and all other reagents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) unless otherwise specified.
Human liver cancer cells. We used human liver cancer HepG2 
cells, which were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). The HepG2 cell line 
was originally derived from a 15-year-old child with primary 
hepatoblastoma (30). Although the HepG2 cells were not 
derived from hepatocellular carcinoma (30), this cell line was 
reported to be genetically the best model for hepatocellular 
carcinoma tumor studies (31).
Colony formation assay. The HepG2 cells were seeded 
into 6-well dishes at a density of 1x103/well, and cultured 
in medium containing 10% FBS, 1% P/S and 1% fungizone 
under 5% CO2 at 37˚C in the presence of either the vehicle 
(1% DMSO) or TCDD (1 or 10 nM) for 14 days, when visible 
clones formed on the plates (32). The dishes were washed with 
PBS (2 ml, 3 times) and fixed with methanol (0.5 ml/well) for 
20 min at room temperature, and then washed 3 times with 
PBS. Finally, colonies were stained with 0.5% crystal violet for 
30 min at room temperature. The stained cells were washed 
5 times with PBS (2 ml). The plates were air-dried for 2 h at 
room temperature. The colonies containing >50 cells were 
counted under a microscope (Nikon TMS, Tokyo, Japan). Data 
were represented as the numbers of colonies per well.
Crystal violet assay. Crystal violet is a basic dye, which stains 
cell nuclei, and spectrophotometric reading of color intensity 
is an indicator of DNA content, and cell number (33). For 
determining cell viability in relation to the colony formation, 
proliferation and death of HepG2 cells, an adaptation of the 
crystal violet staining procedure was applied, as follows: In 
the experiment for cell proliferation, the cells (1x105/ml per 
well) were seeded into 24-well plates and cultured in α-MEM 
(containing 10% FBS, 1% P/S and 1% fungizone) in the pres-
ence of either the vehicle (1% DMSO) or TCDD (1 or 10 nM) 
for 3 days. In the experiment for cell death, the cells (1x105/ml 
per well) were seeded into 24-well plates and cultured in 
α-MEM (containing 10% FBS, 1% P/S and 1% fungizone) 
for 3 days to reach subconfluency. They were then cultured 
for 24 h in the presence of either the vehicle (1% DMSO) or 
TCDD (1 or 10 nM). The cells were washed with PBS and 
fixed with methanol for 20 min at room temperature, and 
then washed 3 times with PBS. Crystal violet solution (0.5%, 
in 20% methanol) was added to the fixed cells for 30 min. 
Thereafter, the plates were immersed in running tap water for 
15 min. After the plates had dried, 300 µl 0.2% Triton X-100 
(in distilled water) was added to each well followed by incuba-
tion at room temperature for 90 min, and 100 µl of the liquid 
content subsequently transferred to 96-well microtiter plates. 
The absorbance (OD) was read on an ELX800 Universal 
Microplate Reader (Bio-Tek Instruments Inc.) at a wavelength 
of 570 nm. Triton X-100 (0.2% in distilled water) was used as 
a blank. The results are presented as absorbance.
Cell proliferation assay. The HepG2 cells (1x105/ml per well) 
were cultured using a 24-well plate in α-MEM (containing 
10% FBS, 1% P/S and 1% fungizone) in the presence of either 
the vehicle (1% DMSO) or TCDD (0.1-1,000 nM) under 
5% CO2 and 37˚C for 1‑7 days (34). In separate experiments, 
the cells (1x105/ml per well) were cultured α-MEM containing 
10% FBS, 1% P/S and 1% fungizone with or without TCDD 
(1 or 10 nM) in the presence of either the vehicle (1% DMSO), 
CH223191 (1 or 10 µM), TNF-α (0.1 or 1 ng/ml), or gemcitabine 
(0.1, 1 or 10 nM) for 3 days. The cells were then detached from 
each culture dish to determine the cell number as described 
below in the section ‘Cell counting’.
Cell death assay. The HepG2 cells (1x105/ml per well) 
were cultured using a 24-well plate in α-MEM (containing 
10% FBS, 1% P/S, and 1% fungizone) in the absence of 
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TCDD for 3 days. On reaching subconfluence, the cells were 
cultured in the presence of either the vehicle (1% DMSO) or 
TCDD (0.1-1,000 nM), with or without the caspase-3 inhibitor 
(10 µM), CH223191 (1 or 10 µM), TNF-α (0.1 or 1 ng/ml), or 
gemcitabine (0.1, 1 or 10 nM) for 24 or 48 h (35). The cells 
were then detached from each culture dish to determine the 
cell number as described below in the section ‘Cell counting’.
Cell counting. To detach cells in each well, the culture dishes 
were incubated for 2 min at 37˚C after the addition of a solution 
(0.1 ml per well) of 0.05% trypsin plus EDTA in Ca2+/Mg2+-free 
PBS, and the cells were detached through pipetting after the 
addition of DMEM (0.9 ml) containing 10% FBS and 1% P/S 
as previously described (34,35). Medium containing the 
suspended cells (0.1 ml) was mixed by the addition of 0.1 ml 
of 0.5% trypan blue staining solution. The number of viable 
cells was counted under a microscope (Olympus MTV-3) with 
a Hemocytometer (Sigma-Aldrich) using a cell counter (Line 
Seiki H-102P; Line Seiki Co., Ltd., Tokyo, Japan). For each 
dish, we took the average of two counts. Cell numbers are 
shown as number per well.
Western blot analysis. In the cell proliferation experiments, 
the HepG2 cells were plated in 100x21 mm dishes at a density 
of 1x106 cells/dish in 10 ml of α-MEM containing 10% FBS, 
1% P/S and 1% fungizone, and the cells were then cultured 
in the presence of either the vehicle (1% DMSO) or TCDD 
(1 or 10 nM) for 3 days. In the cell death experiment, the 
cells (1x106/ml/dish) were seeded in 100x21 mm dishes and 
cultured in 10 ml of α-MEM (containing 10% FBS, 1% P/S 
and 1% fungizone) for 3 days to reach subconfluency. They 
were then cultured for 24 h in the presence of either the vehicle 
(1% DMSO) or TCDD (1 or 10 nM). The cells were washed 
3 times with cold PBS and removed from the dish by scraping 
in cell lysis buffer (Cell Signaling Technology, Danvers, MA, 
USA) supplemented with inhibitors of protease and protein 
phosphatase (Roche Diagnostics, Indianapolis, IN, USA). 
The lysates were then centrifuged at 17,000 x g at 4˚C for 
10 min. The protein concentrations of the supernatants were 
determined using the Bio-Rad Protein Assay Dye (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) with bovine serum 
albumin as a standard. The supernatant was stored at ‑80˚C 
until use. Samples of 40 µg of supernatant protein per lane 
were separated by 12% SDS polyacrylamide gel electropho-
resis (SDS-PAGE), and transferred onto nylon membranes for 
immunoblotting with specific antibodies. Polyclonal AHR 
antibody sheep IgG was obtained from R&D Systems (cat. 
no. AF6697). Other antibodies to signaling proteins, including 
caspase-3 (cat. no. 9662), signal transducer and activator of 
transcription 3 (STAT3) (cat. no. 12640), Ras (cat. no. 14429), 
Akt (cat. no. 9272), mitogen-activated protein kinase (MAPK) 
(cat. no. 4695), β-actin (cat. no. 3700), Rb (cat. no. 9309) 
and p21 (cat. no. 2947) were obtained from Cell Signaling 
Technology (Danvers, MA, USA), and CYP1A1 (cat. 
no. sc-25304), nuclear factor (NF)-κB p65 (cat. no. sc-109), 
β-catenin (cat. no. sc-39350) and p53 (cat. no. sc-126) were 
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA) (36). Rabbit anti-regucalcin antibody was obtained 
from Abcam (Cambridge, MA, USA; diluted 1:1,000; cat. 
no. ab213459), and it was used as previously described (36,37). 
The membranes were incubated with one of the primary 
antibodies (diluted 1:1,000) overnight at 4˚C, followed by 
horseradish peroxidase-conjugated secondary antibodies 
(cat. no. mouse sc-2005 or rabbit sc-2305; Santa Cruz 
Biotechnology, Inc.; diluted 1:2,000). For the AHR antibody, 
we used sheep IgG horseradish peroxidase-conjugated anti-
body (R&D Systems; diluted 1:1,000; cat. no. HAF016). The 
immunoreactive blots were visualized with a SuperSignal 
West Pico Chemiluminescent Substrate detection system 
(Thermo Fisher Scientific, Rockford, IL, USA) according to 
the manufacturer's instructions. β-actin (diluted 1:2,000; cat. 
no. 3700; Cell Signaling Technology) was used as a loading 
control. A minimum of 3 blots from independent experiments 
were scanned on an Epson Perfection 1660 Photo scanner, and 
bands quantified using ImageJ software.
Statistical analysis. Statistical significance was determined 
using GraphPad InStat version 3 for Windows XP (GraphPad 
Software Inc., La Jolla, CA, USA). Multiple comparisons were 
performed by one-way analysis of variance (ANOVA) with the 
Tukey-Kramer multiple comparisons post hoc test for para-
metric data as indicated. A value of P<0.05 was considered to 
indicate a statistically significant difference.
Results
TCDD suppresses on colony formation of HepG2 cells. To 
determine the effects of TCDD on the colony formation of 
HepG2 cells in vitro, the HepG2 cells were cultured in the pres-
ence of TCDD (1 or 10 nM) for 14 days, when visible clones 
were formed on the plates (Fig. 1). Crystal violet is a basic dye 
that stains cell nuclei (33). Colony formation with >50 nuclei 
by estimation with crystal violet staining was suppressed by 
culture with TCDD (1 or 10 nM), as shown in Fig. 1.
TCDD suppresses the growth and proliferation of HepG2 
cells. Cell growth with increasing periods of culture is shown 
in Fig. 2A. Cells reached subconfluency in culture for 3 days 
and to confluency after 4‑7 days of culture in 24‑well plates. At 
3 days after culture in the presence or absence of TCDD (1 or 
10 nM), the cell density was also determined by measuring the 
absorbance of crystal violet in the fixed cells (Fig. 2B and C). 
The spectrophotometer reading of color intensity by staining 
with crystal violet is an indicator of the DNA content and cell 
number (33). Cell growth was clearly suppressed by culture 
with TCDD (Fig. 2B and C). As shown in Fig. 2D and E, repre-
senting growth after 3 and 7 days in culture, respectively, the 
suppression of cell proliferation occurred at a concentration of 
TCDD as low as 0.1 nM
TCDD stimulates the death of HepG2 cells. To investigate 
whether TCDD stimulates the death of HepG2 cells in vitro, 
the cells were cultured for 3 days to reach subconfluency and 
then exposed to TCDD (1 or 10 nM) for a further day. TCDD 
treatment led to cell death. As shown in the images in Fig. 3A 
and by the absorbance (Fig. 3B), TCDD clearly had an effect 
on cell counts at a concentration as low as 0.1 nM both at 
24 and 48 h of treatment after the cells reached subconflu-
ency (Fig. 3C and E). In separate experiments, on reaching 
subconfluency after culture for 3 days, the cells were cultured 
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in the presence of a caspase-3 inhibitor (10 µM) (see Materials 
and methods) for 24 (Fig. 3D) or 48 h (Fig. 3F). The decrease in 
cell number induced by TCDD (1 or 10 nM) was eliminated by 
treatment with the inhibitor of caspase-3. Moreover, the results 
of western blot analysis revealed that the caspase-3 levels were 
increased by culture with TCDD (1 or 10 nM) (Fig. 3G). The 
activation of caspase-3 induces DNA fragmentation related 
to apoptotic cell death (34). Thus, TCDD-induced cell death 
was likely due, at least in part, to an increase in the caspase-3 
levels.
Characterization of the effects of TCDD on the proliferation 
and death of HepG2 cells. To determine the mechanisms 
responsible for the TCDD-induced suppression of the 
proliferation and the stimulation of the death of HepG2 cells, the 
cells were cultured in the presence of CH223191, an inhibitor 
of AHR signaling (31). Western blot analysis identified AHR 
and AHR-inducible CYP1A1, representing a member of the 
cytochrome P450 superfamily of enzymes (1,2), in the HepG2 
cells (Fig. 4A). TCDD (1 or 10 nM) induced a decrease in the 
levels of AHR and a corresponding increase in the levels of 
Figure 2. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) suppresses the proliferation of HepG2 cells in vitro. (A) Cells (1x105 cells/well in 24-well plates) were 
cultured in α-MEM containing 10% FBS for 1-7 days. (B and C) Cells were cultured in α-MEM for 3 days in the presence of either the vehicle or TCDD (1 and 
10 nM), and cells were stained with 0.5% crystal violet. Stained cells are shown in (B) and the absorbance in (C). In a separate experiment, cells (1x105 cells/
well) were cultured in α-MEM containing either the vehicle or TCDD (0.001-100 nM) for 3 days (D) or 7 days (E). After culture, the number of attached 
cells was counted. Data are presented as the means ± SD obtained from 8 wells of 2 replicate plates per data set using different dishes and cell preparations. 
*P<0.001 vs. control (grey bar), determined by one-way ANOVA with the Tukey-Kramer post hoc test.
Figure 1. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) suppresses colony formation of HepG2 cells in vitro. Cells (1x103/well) were seeded into 6-well dishes 
and cultured in α-MEM containing 10% FBS in the presence of either vehicle (1% DMSO) or TCDD (1 or 10 nM) for 14 days when visible clones formed. 
The colonies were washed with PBS and fixed with methanol. Colonies were stained with 0.5% crystal violet. Stained cells are represented as (A) images, 
and (B) colonies containing more than 50 cells were counted under a microscope. *P<0.001 vs. control (gray bar), determined by one-way ANOVA with the 
Tukey-Kramer post hoc test.
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CYP1A1 in the cytosol of the HepG2 cells (Fig. 4A). Culture 
with CH223191 (1 or 10 µM) alone did not exert a significant 
effect on the proliferation (Fig. 4B) or death (Fig. 4C) of the 
HepG2 cells. The suppressive effect of TCDD (1 or 10 nM) 
on the proliferation and the stimulatory effect of TCDD (1 
or 10 nM) on cell death with decrease in attached HepG2 
cells were not caused in the presence of CH223191, although 
the effects of TCDD were not completely blocked by the 
Figure 3. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates the death of HepG2 cells in vitro. (A and B) Cells (1x105 cells in 1 ml per in 24-well plates) 
were cultured in α‑MEM for 3 days to reach subconfluency, and then cultured in α-MEM containing 10% FBS in the presence of either the vehicle (1% DMSO) 
or TCDD (1 or 10 nM) for 24 h, and stained with crystal violet. Stained cells are shown in (A) and absorbance in (B). In separate experiments, subconfluent 
cells were cultured in the presence of either the vehicle or TCDD (0.001-100 nM) for (C) 24 or (E) 48 h, or were cultured for (D) 24 or (F) 48 h in the presence 
of either vehicle or TCDD (1 or 10 nM) with or without caspase-3 inhibitor (10 µM). Following culture, the number of cells attached on dish was counted. 
(G) A total of 1x106 cells were seeded in 100x21 mm dishes and cultured in α‑MEM for 3 days, to reach subconfluency, and then exposed to either the vehicle 
or TCDD (1 or 10 nM) for 24 h. Following culture, the cell lysate (40 µg protein per lane) were applied to SDS‑PAGE for western blot analysis using specific 
antibodies against casapase-3. Data represent results obtained from 3 independent experiments using different cell preparations. Data of cell number (C-F) are 
presented as the means ± SD obtained from 8 wells of 2 replicate plates per data set using different dishes and cell preparations. *P<0.001 vs. control (without 
TCDD), determined by one-way ANOVA with the Tukey-Kramer post hoc test.
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inhibitor (Fig. 4B and C). These findings suggested that the 
effects of TCDD on the proliferation and death of HepG2 cells 
are at least partly mediated through AHR signaling.
The expression of AHR has been shown to be regulated 
by serum and mitogenic growth factors in murine 3T3 fibro-
blasts (38). In this study, we thus examined the effect of the 
serum concentration of TCDD on the proliferation and death 
of HepG2 cells in vitro. Reduced serum concentrations resulted 
in a diminished proliferation of HepG2 cells. The suppressive 
effects of TCDD (1 or 10 nM) on cell proliferation were not 
further enhanced by reducing the serum concentration from 
10 to 1 or 0.1% (Fig. 5A). Cell death was not altered with 
increasing concentrations (0.1, 1 or 10%) of FBS (Fig. 5B). 
Moreover, the stimulatory effects of TCDD (1 or 10 nM) on 
Figure 4. Involvement of the aryl hydrocarbon receptor (AHR) in mediating the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the proliferation and 
death of HepG2 cells. (A) Cells (1x106/ml/dish) were seeded into 100x21 mm dishes and cultured in α-MEM containing 10% FBS in the presence of either the 
vehicle (1% DMSO) or TCDD (1 or 10 nM) for 3 days to reach subconfluency. Cell lysates (40 µg protein per lane) were applied to SDS‑PAGE for western blot 
analysis, using specific antibodies against AHR or CYP1A1. Data represent results obtained from 3 independent experiments using different cell preparations. 
(B) Cells (1x105 cells/per well of ml in 24-well plates) were cultured in α-MEM containing either the vehicle or TCDD (10 nM) for 3 days in the presence of 
CH223191 (1 or 10 µM). (C) Cells (1x105 cells/per well of ml in 24-well plates) were cultured in α‑MEM for 3 days to reach subconfluency. They were then 
were cultured in α-MEM containing either the vehicle or CH223191 (1 or 10 µM). After 1 h, TCDD (10 nM) was added to the medium and the cells cultured 
for a further 23 h. The numbers of attached cells were then counted. Data are presented as the means ± SD obtained from 8 wells of 2 replicate plates per data 
set using different dishes and cell preparations. *P<0.001 vs. control (without TCDD or CH223191). #P<0.01 as compared with the value obtained from TCDD 
alone, determined by one-way ANOVA with the Tukey-Kramer post hoc test.
Figure 5. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the proliferation and death of HepG2 cells are dependent on the concentrations of FBS 
in vitro. (A) Cells (1x105 cells/per well of ml in 24-well plates) were cultured in α-MEM containing different concentrations (10, 1 or 0.1%) of FBS in the 
presence of either the vehicle (1% DMSO) or TCDD (1 or 10 nM) for 3 days. (B) Cells (1x105 cells/per well of ml in 24-well plates) were cultured in α-MEM 
containing 10% FBS for 3 days, and the subconfluent cells were then washed with PBS. The cells were then cultured for 24 h in α-MEM containing different 
concentrations (10, 1 or 0.1%) of FBS in the presence of either vehicle or TCDD (1 or 10 nM). After culture, the number of attached cells were counted. Data are 
presented as the means ± SD obtained from 8 wells of 2 replicate plates per data set using different dishes and cell preparations. *P<0.001 vs. control (the values 
obtained from culture with 10% FBS without TCDD). #P<0.001 as compared with the value obtained from culture with 1% FBS without TCDD, determined 
by one-way ANOVA with the Tukey-Kramer post hoc test.
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cell death with decrease in attached cells were not exhibited 
with a lower concentration (0.1 or 1%) of FBS (Fig. 5B). These 
results indicate that the TCDD-induced suppression of cell 
proliferation and stimulation of cell death were dependent on 
the concentration of serum, which contains various growth 
factors, hormones and cytokines.
TNF-α has been shown to modulate the effects of AHR 
ligands on cell proliferation and expression of cytochrome 
P450 enzymes in rat liver 'stem-like' cells (39). In our experi-
ments, TNF-α (0.1 or 1 ng/ml) suppressed the proliferation 
of HepG2 cells (Fig. 6A) and reduced the number of attached 
cells, indicating increased cell death (Fig. 6B) in vitro. The 
suppressive effects of TCDD (10 nM) on the proliferation and 
the promoting effects on the death of HepG2 cells were not 
potentiated by TNF-α (0.1 or 1 ng/ml) (Fig. 6), suggesting that 
these effects of TCDD are at least partially mediated through 
the activation of NF-κB signaling.
TCDD regulates protein levels linked to certain key 
signaling pathways in HepG2 cells. To further investigate 
the mechanisms of action of TCDD, we examined whether 
TCDD affects the expression of key transcription factors 
and other proteins related to important signaling pathways, 
using western blot analysis. TCDD (10 nM) increased the 
protein levels of NF-κB p65, β-catenin and STAT3, which 
are transcription factors linked to cell signaling (Fig. 7A). 
TCDD (10 nM) also elevated the levels of Ras and Akt, but 
did not alter the level of MAPK, which acts downstream of 
Ras and Akt signaling (Fig. 7A). Of note, TCDD (10 nM) 
markedly increased the expression levels of p53, Rb, 
Figure 7. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) regulates the expression of proteins linked to various signaling pathways in HepG2 cells in vitro. Cells 
(1x106 cells/per dish) were cultured in α-MEM containing 10% FBS in the presence of either vehicle (1% DMSO) or TCDD (1 or 10 nM) for 3 days. After 
culture, the cells were removed from the dish after addition of cell lysis buffer containing protease and protein phosphatase inhibitors. Resulting cell lysates 
were centrifuged to obtain the cytosolic supernatant. Samples of 40 µg of the supernatant protein per lane were separated by SDS-PAGE and transferred 
to nylon membranes for western blot analysis using specific antibodies against various proteins. (A) Cell signaling‑related proteins; (B) tumor suppressor 
proteins. Data represent results obtained from 3 independent experiments using different cell preparations.
Figure 6. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the proliferation and death of HepG2 cells in the presence of TNF-α. (A) Cells (1x105 cells/per 
well in 24-well plates) were cultured in α-MEM containing 10% FBS in the presence of either the vehicle (1% DMSO) or TCDD (10 nM) for 3 days in the 
presence or absence of TNF-α (0.1 or 1 ng/ml). (B) Cells (1x105 cells/per well of ml in 24-well plates) were cultured in α-MEM containing 10% FBS for 3 days, 
and the cells, upon reaching subconfluency after 3 days, were then cultured in α-MEM containing 10% FBS in the presence of either the vehicle or TCDD 
(10 nM) with or without TNF-α (0.1 or 1 ng/ml) for 24 h. Following culture, the numbers of attached cells were counted. Data are presented as the means ± SD 
obtained from 8 wells of 2 replicate plates per data set using different dishes and cell preparations. *P<0.001 vs. control (without both TNF-α and TCDD), 
determined by one-way ANOVA with the Tukey-Kramer post hoc test.
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p21 and regucalcin, which are suppressors of tumor cell 
growth (40,41) (Fig. 7B).
The combination of TCDD and gemcitabine exerts inde-
pendent effects on the proliferation and death of HepG2 
cells. Gemcitabine, an antitumor drug, the action of which 
is not implicated in AHR signaling, is known to suppress 
the proliferation and stimulate the death of cancer cells by 
inducing nuclear DNA damage (42). In this study, the effects 
of TCDD on the proliferation and death of HepG2 cells were 
compared with those of gemcitabine (Fig. 8). Gemcitabine 
(0.1, 1 or 10 nM) suppressed cell proliferation (Fig. 8A) and 
decreased the number of attached cells, indicating increased 
cell death (Fig. 8B). TCDD (0.1 or 1 nM) also suppressed cell 
proliferation and stimulated cell death; the effects of TCDD 
were significantly enhanced in the presence of gemcitabine 
(0.1 or 1 nM) (Fig. 8). These findings suggest that the mode of 
action of TCDD as regards cell proliferation and death differs 
from that of gemcitabine (42). The combination of TCDD and 
gemcitabine may have a potential additive suppressive effect 
on the growth of tumor cells, suggesting a novel strategy in the 
treatment of liver cancer.
Discussion
AHR plays manifold roles in cell differentiation, proliferation 
and organ homeostasis, including in the liver (29). The deple-
tion of AHR induces dedifferentiation and pluripotency in 
normal and transformed cells (29). The activation of AHR has 
been shown to promote the development of liver tumors in a 
model of hepatocarcinogenesis (22,24-26). This receptor may 
also possess tumor suppressor activities in the liver (23,27,28). 
TCDD is a potent activator of AHR signaling. In this study, we 
demonstrated that TCDD at a comparatively lower concentra-
tion, suppressed the formation of colonies and the proliferation 
of human liver cancer HepG2 cells in vitro, and stimulated the 
death of these cells. The TCDD-induced suppression of colony 
formation resulted from both the suppressed proliferation and 
the enhanced death of HepG2 cells. The effects of TCDD on 
the proliferation and death of HepG2 cells were diminished in 
the presence of CH223191, an inhibitor of AHR signaling (31), 
supporting the view that observed TCDD effects are at least 
partly mediated through the AHR signaling pathway.
AHR expression has been shown to be regulated by serum, 
containing mitogenic growth factors in murine 3T3 fibro-
blasts (38). AHR expression has been shown to be diminished by 
culture in a lower concentration of serum (38). Ligand activated 
platelet‑derived growth factor receptor and basic fibroblast 
growth factor receptor, as well as an ectopically expressed 
tyrosine kinase, have been shown to lead to an enhancement of 
AHR expression in the absence of serum (38). Tyrosine kinase 
signaling may be necessary for AHR expression (38). Of note, 
in this study, we found that the suppressive effects of TCDD 
on the proliferation in HepG2 cells were not enhanced with the 
reduction of the serum concentration in vitro. In addition, the 
stimulatory effects of TCDD on the death of HepG2 cells were 
eliminated when the cells were cultured with lower concentra-
tions of serum. Thus, the TCDD-induced suppression of the 
proliferation and the stimulation of the death of HepG2 cells 
were dependent on the concentration of serum, which contains 
various growth factors, hormones and cytokines.
TNF-α, which activates NF-κB signaling, is known to play a 
major role in liver regeneration, as well as in carcinogenesis (39). 
This cytokine has been shown to modulate the effects of AHR 
ligands on proliferation and the expression of cytochrome P450 
enzymes in rat liver ‘stem-like’ cells (39). AHR signaling causes 
NF-κB Rel B activation during dendritic-cell differentiation (43). 
Moreover, TCDD induces hepatic stellate cell activation and 
liver fibrosis in C57BL/6 mice by activating the Akt and NF‑κB 
signaling pathways (44). In the present study, TNF-α suppressed 
the proliferation and stimulated the death of HepG2 cells in vitro; 
however, the suppressive effects of TCDD on the proliferation 
of and its promoting effects on the death of HepG2 cells were 
not potentiated by TNF-α. We also demonstrated that TCDD 
Figure 8. Combination of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and gemcitabine reveals different mechanisms affecting the proliferation and death 
of HepG2 cells in vitro. (A) Cells (1x105 cells/per well in 24-well plates) were cultured in α-MEM containing 10% FBS in the presence of either the vehicle 
(1% DMSO), gemcitabine (0.1, 1 or 10 nM), TCDD (0.1 or 1 nM), or gemcitabine (0.1 or 1 nM) plus TCDD (1 nM) for 3 days. (B) Cells (1x105 cells/per well 
in 24-well plates) were cultured in α‑MEM containing 10% FBS for 3 days, and the cells on reaching subconfluency were then cultured for 24 h in α-MEM 
containing 10% FBS in the presence of either the vehicle, gemcitabine (0.1, 1 or 10 nM), TCDD (0.1 or 1 nM), or gemcitabine (0.1 or 1 nM) plus TCDD (1 nM). 
Following culture, the numbers of attached cells were counted. Data are presented as the means ± SD obtained from 8 wells of 2 replicate plates per data 
set using different dishes and cell preparations. *P<0.001 vs. control (without gemcitabine and TCDD). #P<0.001 as compared with the value obtained from 
gemcitabine or TCDD alone, determined by one-way ANOVA with the Tukey-Kramer post hoc test.
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increased NF-κB p65 expression in HepG2 cells in vitro. These 
observations indicate that the effects of TCDD may be partly 
mediated through the activation of NF-κB signaling.
TCDD has been shown to increase Ras expression in 
studies using transcriptomics and metabonomics to unravel 
modes of action of TCDD in HepG2 cells in vitro (45). In the 
present study, TCDD was also found to increase the levels of 
β-catenin, STAT3, Ras and Akt, all of which are involved in 
cell proliferation and differentiation (32,41), in HepG2 cells. 
These molecules may be partly involved in mediating the 
effects of TCDD on the proliferation and death of HepG2 cells. 
Importantly, we found that TCDD increased the levels of p53, 
Rb, p21 and regucalcin, which each play roles as suppressors of 
the growth of tumor cells (40,41). β-catenin has been reported 
to increase regucalcin expression in HepG2 cells in vitro (46). 
The overexpression of regucalcin has been shown to elevate 
the levels of p53, Rb and p21 in HepG2 cells in vitro (47). It is 
possible that these molecules are partly involved in mediating 
the effects of TCDD on the proliferation and death of HepG2 
cells. It remains to be elucidated, however, whether or not the 
TCDD-induced enhancement of these molecules results from 
the activation of AHR signaling.
Gemcitabine, an antitumor drug, is known to suppress 
the proliferation and stimulate the death of cancer cells by 
inducing nuclear DNA damage (42), although this drug may 
not be linked to AHR signaling. Of note, the suppressive 
effects of TCDD on the proliferation and its promoting effects 
on the death of HepG2 cells, were significantly potentiated by 
gemcitabine. This suggests that the mode of action of TCDD 
on cell proliferation and death differs from that of gemcitabine. 
TCDD has been demonstrated to activate AHR signaling and 
thereby regulate the expression of diverse molecules (1-4). The 
combination of TCDD and gemcitabine may exert a potent 
antitumor effect, suggesting a novel strategy for cancer therapy.
In conclusion, the findings of the present study demon-
strate that TCDD suppresses the growth of human liver cancer 
HepG2 cells in vitro, suppressing colony formation and prolif-
eration and stimulating death, via various signaling pathways. 
TCDD at a comparatively low dose may exert an antitumor 
effect in vivo, suggesting a novel strategy for cancer therapy.
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